The Food and Drug Administration has extended the review period for sparsentan in focal segmental glomerulosclerosis (FSGS).

Please provide your email address to receive an email when new articles are posted on . Researchers identified functionally relevant risk factors for pediatric primary focal segmental ...

Focal segmental glomerulosclerosis (FSGS) is a rare kidney disorder that affects children and adults, and can lead to kidney failure. New findings from a team led by the University of Minnesota ...

Please provide your email address to receive an email when new articles are posted on . Among patients with focal segmental glomerulosclerosis, immunosuppressant therapy reduced proteinuria but showed ...

EXTON, Pa., March 22, 2021 /PRNewswire/ — Glomerular diseases, including IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), and Alport Syndrome, among others, together amount to the ...

Focal segmental glomerulosclerosis (FSGS) still lacks an FDA-approved therapy, but late-breaking post hoc results from the phase III DUPLEX trial -- presented at the National Kidney Foundation Spring ...

TOKYO, Oct. 17, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") today announced that it has reached an agreement with the Pharmaceuticals and Medical Devices Agency ...

Clinical trial evaluating changes in urine protein-to-creatinine ratio, a widely-accepted endpoint measuring risk reduction of kidney failureCAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Akebia ...